查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600410

老龄化黄斑部病变市场：按类型、治疗方法、交付方法、医疗环境、分销管道 - 2025-2030 年全球预测

Age-related Macular Degeneration Market by Type, Treatment Modality, Delivery Method, Healthcare Setting, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，老龄化黄斑部病变市场价值为104.5亿美元，预计到2024年将达到111亿美元，复合年增长率为6.67%，到2030年将达到164.3亿美元。

老龄化黄斑部病变（AMD）是一个主要的公共卫生问题，也是全世界老年人视力丧失的主要原因。 AMD 市场包括药物治疗，例如抗血管内皮生长因子（抗 VEGF）治疗，以及新兴的基因和干细胞治疗。随着世界人口老化和盛行率的增加，AMD 治疗方法的进步更加迫切，从而推动了对更有效、更容易获得的治疗方法的需求。最终用途广泛，包括医院、眼科诊所和研究机构。影响成长的关键因素包括医疗保健支出的增加、生物医学技术的进步以及对 AMD 早期检测和管理的认识的提高。特别是，新兴经济体中老年人数量的增加代表着一个重大的商机。公司可以透过投资研发来利用这些机会，以创新更有效和更安全的治疗方法。建议与医疗保健提供者和患者倡导组织建立合作伙伴关係，以加强市场推广。

主要市场统计
基准年[2023] 104.5亿美元
预测年份 [2024] 111亿美元
预测年份 [2030] 164.3亿美元
复合年增长率（%） 6.67%

目前的 AMD 治疗方法具有较高的治疗成本、监管挑战和潜在的副作用，限制了市场的扩张。此外，AMD发病机制的复杂性使得很难开发出一刀切的解决方案，凸显了个人化医疗的必要性。创新可以集中在基因研究上，以发现新的生物标记物，用于早期诊断和更个人化的治疗方法。此外，对提高治疗依从性和患者预后的药物传递系统的投资似乎也很有希望。市场竞争激烈，涉及大型製药公司、生物技术公司和学术研究机构，使其成为一个动态的局面，需要战略灵活性。作为一种补充方法，公司应该使其产品组合多样化，包括替代疗法，例如已知支持黄斑部健康的营养食品。与诊断支援和远端医疗领域的人工智慧技术进步保持同步也有可能开拓新市场。

市场动态：揭示快速发展的老龄化黄斑部病变市场的关键市场洞察

供需的动态交互作用正在改变老龄化黄斑部病变市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界各地老年人口不断增加
    • 雷射疗法和血管生成抑制剂的使用迅速增加
    • 增加诊断设施和技术以有效侦测AMD
  • 市场限制因素
    • AMD相关药物召回的潜在风险
  • 市场机会
    • AMD重要的政府政策和资金支持
    • 透过细胞疗法和组织工程采用新的先进疗法
  • 市场问题
    • 严格的法规环境和新治疗方法的复杂核准

波特五力：驾驭老龄化黄斑部病变市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对老龄化黄斑部病变市场的影响

外部宏观环境因素在塑造老龄化黄斑部病变市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解老龄化黄斑部病变市场的竞争格局

对老龄化黄斑部病变市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：老龄化黄斑部病变市场的供应商绩效评估

FPNV定位矩阵是评估老龄化黄斑部病变市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製老龄化黄斑部病变市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对老龄化黄斑部病变市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地老年人口数量不断增加
      • 雷射疗法和抗血管新生药物的使用迅速增加
      • 增加诊断设施和技术以有效检测 AMD
    • 抑制因素
      • AMD相关药物召回的潜在风险
    • 机会
      • AMD 的重要政府政策与资金
      • 采用细胞疗法和组织工程的新先进治疗方法
    • 任务
      • 严格的法规环境和新治疗方法的复杂核准
  • 市场区隔分析
    • 类型：个人化治疗针对干性 AMD 逐渐和快速视力丧失
    • 治疗方法：老龄化黄斑部病变的综合管理和创新药物治疗
    • 给药方式：针对老龄化黄斑部病变的创新註射方法
    • 医疗机构：透过 ASC、医院和诊所提供先进且经济有效的治疗方法，为 AMD 管理提供全面护理
    • 分销管道：分销 AMD 药物的线上药局激增，以确保全面的患者照护
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境
  • 客户客製化
    • 各国接受治疗的患者人数及平均治疗费用

第六章老龄化黄斑部病变市场：依类型

  • 介绍
  • 湿性老龄化黄斑部病变
  • 干老龄化黄斑部病变

老龄化黄斑部病变市场：治疗方法

  • 介绍
  • 药品
    • 发炎药
    • 抗VEGF剂
    • 抗氧化剂和补充品
    • 基因治疗
  • 手术介入
    • 雷射治疗
    • 黄斑移位手术
    • 动态疗法
    • 玻璃体切除手术

老龄化黄斑部病变市场：按交付方式

  • 介绍
  • 注射
  • 玻璃体内植入
  • 口服

老龄化黄斑部病变市场：依医疗环境分类

  • 介绍
  • 门诊手术中心
  • 医院
  • 眼科诊所

老龄化黄斑部病变市场：按分销管道

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第十一章美洲老龄化黄斑部病变市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太老龄化黄斑部病变市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲老龄化黄斑部病变市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 基因泰克重新推出“Susvimo”，一种改善视力的湿性AMD治疗方法
    • Stealth BioTherapeutics 开始 Elamipretide 预防皮肤干燥并改善患者治疗效果的 3 期试验
    • LambdaVision 获得资金以推进创新视网膜假体的临床前测试
    • Science Corporation 收购 Pixium Vision 的 PRIMA 视网膜植入，帮助 AMD 患者恢復视力
    • 香港医科大学研究人员开发创新光激活奈米药物以实现更安全、更有效的治疗
    • EyeBio 获得 1.3 亿美元 A 轮资金筹措，推进针对老龄化黄斑部病变的 Restoret 疗法
    • 安斯泰来製药宣布有望有效且安全地治疗老龄化黄斑部病变
    • FDA核准针对 Aviceda Therapeutics 的 AVD-104 治疗老龄化黄斑部病变的临床试验
    • 视网膜变性基金的主要投资促进生物技术、推进老龄化黄斑部病变治疗并改善生活质量
  • 战略分析和建议
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Bayer AG
    • Astellas Pharma Inc.

公司名单

  • AbbVie Inc.
  • Adverum BIoTechnologies, Inc.
  • Alkeus Pharmaceuticals, Inc.
  • Allegro Ophthalmics, LLC
  • Amgen Inc.
  • Annexon, Inc.
  • Apellis Pharmaceuticals, Inc.
  • AsclepiX Therapeutics
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biocon Ltd
  • Biogen Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Formycon AG
  • Grifols, SA
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lineage Cell Therapeutics, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • PanOptica, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz Group AG
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-F927BA46233D

The Age-related Macular Degeneration Market was valued at USD 10.45 billion in 2023, expected to reach USD 11.10 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 16.43 billion by 2030.

Age-related Macular Degeneration (AMD) represents a significant public health concern, being a leading cause of vision loss among the elderly population globally. The market scope encompasses pharmacological therapies, such as anti-vascular endothelial growth factor (anti-VEGF) treatments, along with emerging gene therapies and stem cell approaches. The necessity for advancing AMD therapeutics is underscored by an aging global population and increasing disease prevalence, driving demand for more effective and accessible treatments. Applications extend primarily to the ophthalmology sector, targeting both wet and dry forms of AMD, with end-use spanning hospitals, specialized eye clinics, and research institutions. Key factors influencing growth include rising healthcare expenditure, advancements in biomedical technology, and increasing awareness of early AMD detection and management. Notably, the growing geriatric population in developing economies presents substantial opportunity. Companies can leverage these opportunities by investing in R&D to innovate treatments with better efficacy and safety profiles. Collaborative partnerships with healthcare providers and patient advocacy groups are recommended to enhance market outreach.

KEY MARKET STATISTICS
Base Year [2023] USD 10.45 billion
Estimated Year [2024] USD 11.10 billion
Forecast Year [2030] USD 16.43 billion
CAGR (%) 6.67%

Nonetheless, market expansion faces limitations due to high treatment costs, regulatory challenges, and potential side effects associated with current AMD therapies. Moreover, the complexity of AMD's etiology complicates the development of one-size-fits-all solutions, emphasizing the need for personalized medicine. Innovation could focus on genetic research to uncover new biomarkers for earlier diagnosis or more tailored therapeutic regimens. Additionally, investment in drug delivery systems that enhance treatment adherence and patient outcomes could be promising. The market is competitive and involves major pharmaceutical companies, biotech firms, and academic research institutions, creating a dynamic landscape that requires strategic agility. Companies should diversify their portfolio to include alternative therapies like nutraceuticals known to support macular health as complementary approaches. Keeping pace with technological advancements in AI for diagnostic support and telemedicine also holds potential for new market endeavors.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing number of geriatric population across the world
    • Surging use of laser therapy and anti-angiogenesis drugs
    • Increasing diagnostics facilities and technology for effective detection of AMD
  • Market Restraints
    • Potential risk of drug recalls associated with AMD
  • Market Opportunities
    • Significant government policies & funding for AMD
    • Introduction of novel and advanced treatments based on cell therapy and tissue engineering
  • Market Challenges
    • Stringent regulatory environment and complex approval of new treatments

Porter's Five Forces: A Strategic Tool for Navigating the Age-related Macular Degeneration Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Age-related Macular Degeneration Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Age-related Macular Degeneration Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Age-related Macular Degeneration Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Age-related Macular Degeneration Market

A detailed market share analysis in the Age-related Macular Degeneration Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Age-related Macular Degeneration Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Age-related Macular Degeneration Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Age-related Macular Degeneration Market

A strategic analysis of the Age-related Macular Degeneration Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., AsclepiX Therapeutics, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biocon Ltd, Biogen Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Formycon AG, Grifols, S.A., Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., Lupin Limited, Merck & Co., Inc., Nicox S.A., Novartis AG, PanOptica, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz Group AG, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Age-related Macular Degeneration Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration.
  • Based on Treatment Modality, market is studied across Pharmaceuticals and Surgical Interventions. The Pharmaceuticals is further studied across Anti-inflammatory Drugs, Anti-VEGF Agents, Antioxidants & Supplements, and Gene Therapy Drugs. The Surgical Interventions is further studied across Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and Vitrectomy.
  • Based on Delivery Method, market is studied across Injectable, Intravitreal implants, and Oral.
  • Based on Healthcare Setting, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmology Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of geriatric population across the world
      • 5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
      • 5.1.1.3. Increasing diagnostics facilities and technology for effective detection of AMD
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of drug recalls associated with AMD
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant government policies & funding for AMD
      • 5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environment and complex approval of new treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Targeting gradual vision loss in dry AMD and rapid impairment with tailored treatments
    • 5.2.2. Treatment: Comprehensive management and innovative pharmaceutical treatments in age-related macular degeneration
    • 5.2.3. Delivery Method: Innovative injectable methods for age-related macular degeneration
    • 5.2.4. Healthcare Setting: Comprehensive care in AMD management through ASCs, hospitals, and clinics with advanced and cost-effective treatments
    • 5.2.5. Distribution Channel: Proliferation of online pharmacies for distributing AMD drugs to ensure comprehensive patient care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Number of Patients Undergoing Treatments and Average Cost of Treatment By Country

6. Age-related Macular Degeneration Market, by Type

  • 6.1. Introduction
  • 6.2. Dry Age-Related Macular Degeneration
  • 6.3. Wet Age-Related Macular Degeneration

7. Age-related Macular Degeneration Market, by Treatment Modality

  • 7.1. Introduction
  • 7.2. Pharmaceuticals
    • 7.2.1. Anti-inflammatory Drugs
    • 7.2.2. Anti-VEGF Agents
    • 7.2.3. Antioxidants & Supplements
    • 7.2.4. Gene Therapy Drugs
  • 7.3. Surgical Interventions
    • 7.3.1. Laser Therapy
    • 7.3.2. Macular Translocation Surgery
    • 7.3.3. Photodynamic Therapy
    • 7.3.4. Vitrectomy

8. Age-related Macular Degeneration Market, by Delivery Method

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Intravitreal implants
  • 8.4. Oral

9. Age-related Macular Degeneration Market, by Healthcare Setting

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Ophthalmology Clinics

10. Age-related Macular Degeneration Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Age-related Macular Degeneration Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Age-related Macular Degeneration Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Age-related Macular Degeneration Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Genentech relaunches Susvimo for wet AMD with improved vision
    • 14.3.2. Stealth BioTherapeutics launches phase 3 trial for elamipretide to combat dry age-related macular degeneration and improve patient outcomes
    • 14.3.3. LambdaVision secures funding to advance preclinical trials of innovative artificial retina
    • 14.3.4. Science Corporation acquires Pixium Vision's PRIMA retinal implant to enhance vision restoration for AMD patients
    • 14.3.5. Researchers at HKUMed develop groundbreaking photoactivatable nanomedicine for safer and more effective age-related macular degeneration treatment
    • 14.3.6. EyeBio secures USD 130 million Series A funding to advance Restoret therapy for age-related macular degeneration treatment
    • 14.3.7. Astellas Pharma unveils treatment for age-related macular degeneration with promising efficacy and safety results
    • 14.3.8. FDA provides clearance of clinical trials for Aviceda Therapeutics' AVD-104 targeting age-related macular degeneration
    • 14.3.9. Retinal Degeneration Fund's major investment boosts biotech to advance age-related macular degeneration treatments and improve quality of life
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. F. Hoffmann-La Roche Ltd.
    • 14.4.2. Novartis AG
    • 14.4.3. Bayer AG
    • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adverum Biotechnologies, Inc.
  • 3. Alkeus Pharmaceuticals, Inc.
  • 4. Allegro Ophthalmics, LLC
  • 5. Amgen Inc.
  • 6. Annexon, Inc.
  • 7. Apellis Pharmaceuticals, Inc.
  • 8. AsclepiX Therapeutics
  • 9. Astellas Pharma Inc.
  • 10. Bausch Health Companies Inc.
  • 11. Bayer AG
  • 12. Biocon Ltd
  • 13. Biogen Inc.
  • 14. Clearside Biomedical, Inc.
  • 15. EyePoint Pharmaceuticals, Inc.
  • 16. F. Hoffmann-La Roche Ltd.
  • 17. Formycon AG
  • 18. Grifols, S.A.
  • 19. Ionis Pharmaceuticals, Inc.
  • 20. Johnson & Johnson Services, Inc.
  • 21. Kodiak Sciences Inc.
  • 22. Lineage Cell Therapeutics, Inc.
  • 23. Lupin Limited
  • 24. Merck & Co., Inc.
  • 25. Nicox S.A.
  • 26. Novartis AG
  • 27. PanOptica, Inc.
  • 28. Pfizer Inc.
  • 29. Regeneron Pharmaceuticals, Inc.
  • 30. Sandoz Group AG
  • 31. Sun Pharmaceutical Industries, Ltd.
  • 32. Teva Pharmaceutical Industries Ltd.
  • 33. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
  • FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AGE-RELATED MACULAR DEGENERATION MARKET DYNAMICS
  • TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTIOXIDANTS & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY MACULAR TRANSLOCATION SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN AGE-RELATED MACULAR DEGENERATION